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Ending Eclampsia seeks to expand access to proven, under-utilized interventions and commodities  
for the prevention, early detection, and treatment of pre-eclampsia and eclampsia and strengthen global 
partnerships. This research report is part of series of implementation research activities conducted by the 
Ending Eclampsia project in Nigeria and focuses on assessing the feasibility and acceptability of community 
health extension workers at the primary healthcare level to identify and treat pregnancy associated 
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This report is based on implementation research findings on assessing the feasibility and acceptability of 
Community Health Extension Workers at primary healthcare centers to identify and treat pregnancy 
associated hypertension using Alpha Methyldopa (Aldomet). 
We acknowledge all stakeholders (professional associations and implementing partners) who provided 
valuable inputs during the study and dissemination of findings. The successful completion of this research 
would not have been possible without the enabling environment provided by the Federal Ministry of Health 
and of Ebonyi State Ministry of Health and the dedication of Community Health Extension Workers in the 
participating health facilities. We further acknowledge all the study participants, who gave their time and 





Hypertensive disorders in pregnancy, experienced by 10 percent of women globally, are major contributors 
to maternal and newborn mortality, morbidity, and disability. Task shifting essential health services to 
mitigate insufficient human resources is recommended to strengthen and expand the health work force to 
rapidly increase access to quality services. Nigeria’s task shifting policy recommends that community 
health extension workers administer a loading dose of magnesium sulphate prior to referral for severe pre-
eclampsia or eclampsia to a higher level facility. The success achieved with magnesium sulphate task 
shifting to lower level health facilities has not been widely explored with anti-hypertensive drugs to control 
high blood pressure in pregnant women.  
This study tested the feasibility and acceptability of community health extension workers at primary 
healthcare facilities in Ebonyi state to detect and manage pregnancy-associated hypertension using alpha 
methyldopa and magnesium sulphate where appropriate and refer for follow up. Baseline data were 
collected from 10 of 13 local government areas in 40 primary healthcare centers (20 interventions and 20 
comparison) in 2016 and endline in November 2017. 
In intervention arm only, community health extension workers were trained and mentored to detect, classify 
and manage hypertension associated with pregnancy, pre-eclampsia and eclampsia and refer to their 
affiliated secondary health facilities according to clinical protocols. For pregnant women identified with 
hypertension with or without significant proteinuria, they were recruited into the study and subsequently 
followed-up post-delivery. If a woman’s blood pressure was not controlled, women were referred to a higher 
facility. For women with severe pre-eclampsia and eclampsia, they received a loading dose of magnesium 
sulphate and were referred. 
Community health extension workers in the comparison arm received no training or mentorship; and 
continued with their usual practice of administering a loading dose of magnesium sulphate to women with 
severe pre-eclampsia/eclampsia and referral. 
More community health extension workers in the intervention arm correctly identified normal blood 
pressure, and differentiated as well as managed, mild, moderate, and severe hypertension than those in 
the comparison arm. This included a 72 percent knowledge improvement in when to introduce anti-
hypertensives versus a three percent improvement in the comparison arm; and were three times more 
likely to identify alpha methyldopa as a specific drug to control blood pressure at endline. Significant 
differences were also observed in knowledge and ability to categorize the various hypertensive disorders 
in pregnancy correctly. In both arms, community health extension workers were most likely to prescribe 
alpha methyldopa (60% and 50% respectively) at endline. Among women with moderate-to-severe 
hypertension who required anti-hypertensives upon diagnosis, more women in the intervention arm 
received treatment than women in the comparison arm. 
During the study, five maternal deaths occurred: one intrapartum death from the intervention arm and four 
from the comparison arm (one antepartum, 2 intrapartum, one postpartum). The woman who died in the 
intervention arm did not receive a loading dose of Magnesium Sulphate following diagnosis of severe pre-
eclampsia (all women who received a loading dose survived). A total of 13 fetal deaths also occurred: four 
in the intervention arm (3 stillbirths and one early neonatal death) and nine to the comparison arm (all 
stillbirths). None of the mothers of the babies who died received a loading dose of magnesium sulfate.  
Community health extension workers at primary health care facilities can correctly measure blood pressure, 
detect abnormal blood pressure, and treat accordingly for severe pre-eclampsia and eclampsia, and refer 
to a higher facility for further management. Although challenges remain in ensuring sufficient commodities 
and supplies are continuously available, this study demonstrates how ministries of Health might use these 
missed opportunities to detect pre-eclampsia (and potentially other conditions) and prevent deterioration 





Hypertensive disorders in pregnancy (HDPs), experienced by 10 percent of women globally, are major 
contributors to maternal and newborn mortality, morbidity, and disability1-2. HDPs include pre-eclampsia, 
gestational hypertension (hypertension), and chronic hypertension during pregnancy. Pre-eclampsia, 
defined as hypertension with significant proteinuria after 20 weeks’ gestation in pregnancy, complicates 
two to eight percent of pregnancies3, 4. In low- and middle-income countries (LMICs), a woman is seven 
times more likely to develop pre-eclampsia than a woman in a high income country. Some 10 percent to 
25 percent of women who suffer from pre-eclampsia likely will die5, 6. About 10 percent of women with pre-
eclampsia develop severe pre-eclampsia and eclampsia6-7. Of the 10 to 25 percent of the pre-eclampsia 
and eclampsia (PE/E)-related maternal deaths worldwide, eclampsia accounts for about 14 percent5, 8.  
In recent years, there has been increased recognition and support for the use of magnesium sulphate 
(MgSO4) as a life-saving and cost-effective maternal health commodity, both as prophylaxis and treatment 
for convulsions due to severe PE/E9-17. Similar attention has not been given to identifying and managing 
hypertension associated with PE/E, as well as other forms of hypertension seen in pregnancy. Failure to 
address hypertension minimizes the gains in institutionalizing MgSO4 in a health system for PE/E 
management.  
Globally, task shifting essential health services to accommodate insufficient human resources is 
recommended for strengthening and expanding health workforces for rapid increases in access to quality 
services18-19. Specific reorganization and decentralization recommended by the World Health Organization 
(WHO) is due to the knowledge that lower level cadres such as auxiliary nurse and midwives can administer, 
with targeted monitoring and evaluation (M&E), anti-hypertensive drugs for severe HDP19. Less, however, 
is known about the abilities of community health extension workers—the main figures in primary health 
care (PHC) in Nigeria—and their suitability to provide anti-hypertensive services. CHEWs are a lower level 
service provider cadre with more training than an auxiliary nurse or midwife (as defined by WHO).  
CHEWs in Nigeria receive three years of pre-service training and community experience, so it is conceivable 
they could also be provided with appropriate knowledge, skills, and training for managing moderate and 
severe hypertension using anti-hypertensive drugs recommended for use in pregnancy, and then referring 
women to higher levels for follow up care, if appropriate. 
In Nigeria, HDPs—principally PE/E—account for over 23 percent of deaths among pregnant women6. 
Programs for averting PE/E mortality and morbidity have made MgSO4 routinely available, with some 
success9,11,20. These efforts have also implemented task shifting for CHEW administration of a loading dose 
of MgSO4 prior to referrals to a higher level facility for severe PE/E 20-21. The successes achieved with MgSO4 
task shifting to lower level health facilities has not been widely transferred to anti-hypertensive drugs for 
controlling high blood pressure (BP) in pregnant women prior to referral.  
Rapidly increasing BP may result in cerebrovascular accident (CVA), a known cause of death in women with 
PE/E. Addressing HDP in a timely and effective way reduces maternal morbidity and mortality, but emphasis 
has varied on how to achieve this goal, with more attention to MgSO4 and less emphasis on studying the 
administration of anti-hypertensive drugs21. Before 2013 in Nigeria, CHEWs at PHCs were not authorized 
to administer MgSO4 for severe PE/E due to perceptions of insufficient training22. A quasi-experimental 
pilot study in Kano state showed that MgSO4 task shifting (initial dose for women with severe PE/E, and 
referral to secondary hospitals) to CHEWs at PHCs resulted in demonstrable improvements in maternal and 
neonatal survival20. The study trained CHEWs, with one year of follow up, M&E, and supportive supervision. 
Presentation of these findings at the 2012 National Council of Health (NCH) of Nigeria contributed to the 




Although HDP treatment by PHC CHEWs is not recommended in Nigeria’s current national task shifting 
policy, a 2015 analysis in seven Nigerian states, of service providers’ knowledge and practices, and 
pregnant women’s and community members’ understanding, of PE/E found that 41 percent of PHC 
providers (mainly CHEWs) reported prescribing anti-hypertensive drugs—some not recommended in 
pregnancy—to pregnant women 23. It is imperative to provide appropriate anti-hypertensive drugs to 
pregnant women with moderate to severe HDP, and at their first contact with the health system.   
CHEWs are currently not authorized to prescribe anti-hypertensive drugs but can refer pregnant women 
with high BP to a secondary hospital, although they may have the capacities to treat women on site21. This 
is contrary to other countries’ practices and WHO recommendations for task shifting to lower level cadres18-
19. This study tested the feasibility and acceptability of Nigeria’s PHC CHEWs to detect and manage HDP 
using alpha methyldopa, including administration of MgSO4 and referral to higher level care, where 
appropriate. 
STUDY GOALS AND OBJECTIVES 
The overall aim of this study was to assess the feasibility and acceptability of CHEWs’ detection and 
management of HDP using alpha methyldopa. The specific objectives were to:  
 Assess the feasibility of CHEWs’ detection and classification of high BP among pregnant women 
during antenatal care (ANC) contacts,  
 Assess CHEWs’ abilities to prescribe an anti-hypertensive drug (alpha methyldopa) for pregnant 
women with moderate hypertension, and  
 Assess CHEWs’ abilities to prescribe appropriate an anti-hypertensives drug (alpha methyldopa) 
for pregnant women with severe hypertension during PE/E prior to referral, including prescribing 
















This study was conducted in southeastern Nigeria’s Ebonyi 
state, comprised of 13 local government areas (LGAs). 
Ebonyi is one of the three states where Population Council 
implemented the Ending Eclampsia project, a larger effort 
supporting PE/E prevention, early detection, and 
management at lower health system levels23. Ebonyi has 
the worst health indices among Nigeria’s southeastern 
states, similar to many northern states; but its level of 
education is generally higher than the north, which makes 
Ebonyi a conducive setting for this study.  
Nigeria’s health system is designed for a secondary health care facility (i.e. hospital) in each LGA, to which 
four PHC facilities are referring facilities. Ebonyi state has 13 secondary hospitals and 52 PHC facilities. 
Statutorily, CHEWs staff all PHC facilities in Nigeria, including in Ebonyi state. 
HOW INTERVENTIONS WERE OPERATIONALIZED 
PHC CHEWs were trained and mentored by this study to detect, classify, and manage HDP, including 
referring patients to affiliated secondary hospitals. Hypertensive disorders investigated included chronic 
hypertension (defined as isolated hypertension diagnosed before the index pregnancy or detected before 
20 weeks of gestation), gestational hypertension (isolated hypertension diagnosed for the first time after 
20 weeks of index pregnancy without proteinuria), and pre-eclampsia (gestational hypertension and 
proteinuria of ≥ ++ using a urine dipstick). Hypertension was defined as a systolic BP (sBP) of ≥140mmHg 
and or diastolic BP (dBP) of ≥90mmHg measured on two different occasions, four to six hours apart. In 
some cases, where distance was a factor, clients stayed at the facility for repeat measurement; if clients 
lived nearby, they were instructed to return. 
CHEWs were trained and mentored to correctly diagnose hypertension as chronic, gestational, or as PE/E. 
Training also featured hypertension classification—as mild, moderate, or severe—and either pre-eclampsia 
or severe pre-eclampsia. For mild hypertension, CHEWs were trained to only regularly monitor BP. For 
moderate hypertension, CHEWs prescribe alpha methyldopa. For severe hypertension, in addition to 
continued alpha methyldopa, CHEWs were advised to refer clients to a higher level facility, and if associated 
with severe pre-eclampsia, CHEWs administered a loading dose of MgSO4 before referral (see Table 1). 
FACILITY SELECTION AND CHEWS IDENTIFICATION AND TRAINING 
In collaboration with Ebonyi state’s Ministry of Health (SMoH), Ending Eclampsia randomly selected 10 
LGAs: five (featuring 20 PHC facilities) to serve as intervention sites and the other five (also with 20 PHCs) 
as comparison sites. Both the intervention and comparison arms were already trained and authorized to 
administer a loading dose of MgSO4 for severe PE/E. CHEWs conducting antenatal care (ANC) services in 
the intervention arm were then also trained to detect and classify HDP, including treatment with alpha 
methyldopa and a loading dose of MgSO4, when appropriate. CHEWs in the comparison arm received no 
such training and mentorship, and were to continue usual practice, which includes administering a loading 
dose of MgSO4 to women with severe PE/E, as recommended by the national task shifting policy, for 
referring women with high BP during pregnancy. 
EBONYI  STATE,  NIGERIA  
 Total Population: 2.2 Million  
(2006 census) 
 ANC attendance: 85% 
 Health facility deliveries: 60% 
 Postnatal care within 48 hours  
of delivery: 55% 
 Mean age at first delivery: 21. 4 
 Total fertility rate: 5.3 




Table 1: Diagnostic and management algorithm used for this study 




(140 – 149/ 90 – 99mmHg) 
Monitor BP closely 
No anti-hypertensive 













Refer to higher level facility 
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Hypertension 
140 – 149/ 90 – 99mmHg 
Monitor BP closely 
No anti-hypertensive 
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Pre-eclampsia 
Mild Hypertension 
(140 – 149/ 90 – 99mmHg) 
Monitor BP closely 
No anti-hypertensive 













loading dose of MgSO4 
Refer to higher level facility 
Eclampsia  Loading dose of MgSO4 
Refer immediately to higher 
level facility 
 
In October 2016, CHEWs in the intervention arm attended a three day, competency-based training 
workshop. A group of master trainers (MTs) and trainers selected from SMoH and Ob/Gyn and midwifery 
professionals was established. Pre- and post-training tests assessed immediate changes in knowledge. The 
training curriculum was based upon WHO as well as the national guidelines for HDP management 24.  
Treatment protocols and a referral decision-making tree for HDPs (also developed based upon WHO 
recommendations) were provided to CHEWs, to guide identification and treatment for women with HDPs. 
The protocol and decision-making tree describe ways to identify HDP during ANC (and PNC) and to 
categorize hypertension as chronic, gestational, or as pre-eclampsia. Furthermore, the guidelines provide 
information for grading hypertension as mild, moderate, and severe, and management of each category. 
Training also emphasized how to correctly determine BP, conduct urine protein testing with dipstick, and 
when to administer anti-hypertensive drugs (alpha methyldopa, Aldomet), as well as counseling clients and 
referral processes. CHEWs were also instructed how to document the essential elements of their ANC 
services, for example BP and urine results, past medical history, gestational age, and identifying danger 
signs and symptoms in pregnancy. Details of counseling and referral, including policy guidelines for referral 
and the importance of adherence to referral, were emphasized. CHEWs were also oriented on the study 
procedures, ethical issues, as well as the participant enrollment processes.  
CHEWs in the comparison arm did not receive any training on HDP detection and management (other than 
standard CHEW services in Nigeria, which includes administering a loading dose of MgSO4 to women with 
severe PE/E, and referral).  
CHEWs’ training on HDP diagnosis, classification, and management was based upon the algorithm shown 






Figure 1: Flow chart for diagnosing and managing hypertension in pregnancy for this study 





CLIENT IDENTIFICATION  
Pregnant women attending an ANC clinic were screened for hypertension and proteinuria. For women with 
high BP or significant proteinuria, CHEWs documented their socio-demographic characteristics, obtained 
informed consent, and recruited them into the study. Only hypertensive pregnant women 15 years or older 
were enrolled. Although the age of consent in Nigeria is 18 years, pregnant women younger than 18 are 
considered emancipated by virtue of their pregnancy status. And in addition, the national policy for research 
with adolescents indicates that adolescents can make informed decisions about their medical needs25.  
CHEWs opened a treatment folder for each client, in which all clinical decisions and medical interventions 
were documented. Each recruited client was followed until her delivery, and into the immediate postpartum 
period (up to 48 hours) to determine if she was managed according to the guidelines. Permission for a 
follow up call was obtained during the informed consent process.  
CLIENT REFERRAL 
Guided by the decision-making tree (job aid and treatment algorithm, see Figure 1), if a woman’s BP was 
not controlled, she was referred to a physician at a secondary- or higher level facility. When a woman had 
severe PE/E, she was administered a loading dose of MgSO4, according to the national standard, and 
referred to a higher level facility for definitive management. CHEWs displayed job aids in their consultation, 
treatment, and labor rooms for ease of reference.   
To track referrals, CHEWs issued a duplicate copy of a client’s completed case notes for the client to take 
to the referral facility; then, if a client did not present at a referral facility, the CHEW called the client or her 
family directly. In the comparison arm, CHEWs were encouraged to refer clients with severe cases to higher 
level facilities for definitive management, but they did not receive training on how to identify and manage 
HDPs.  
SUPPLY OF ANTI-HYPERTENSIVE DRUGS (ALPHA METHYLDOPA) 
Before commencing the study, consultative meetings with Ebonyi SMoH requested their procurement, 
supply, and monitoring of uptake of anti-hypertensive drugs (alpha methyldopa only) among the study’s 
intervention facilities, staff, and clients. Initial doses of alpha methyldopa were prescribed by CHEWs and 
obtained from facilities’ pharmacies. If stock outs occurred during the study, clients were asked to obtain 
the drug at a local pharmacy (while efforts were being made to replenish facility supplies). Women were 
instructed to return for prescription refills at the health facility; BP was re-checked at every visit. 
CHEW SUPPORTIVE SUPERVISION AND JOB AIDS 
Chews were monitored and mentored monthly, and clients’ records were reviewed during each monitoring 
visit to ensure chew compliance with ethical and clinical standards. This monthly supportive supervision 
was in collaboration with Ebonyi SMoH. A SMoH physician provided M&E and supervision for the 
management of any adverse events of drugs. During supportive supervision visits, chews were observed 
for how they measured and determined BP and tested for urine proteins. In instances with no incidences 








SAMPLING, DATA COLLECTION AND ANALYSIS 
The study’s design was quasi-experimental and a non-equivalent comparison, in which 40 PHC facilities 
from 10 LGAs were divided into two arms (5 LGAs in each arm)—experimental and comparison. Four PHC 
facilities were selected within each, LGA for a total of 20 facilities per study arm. There were three periods 
of data collection during implementation—at baseline in October 2016, immediate post-training in 
November 2016, and endline in November 2017. 
At baseline, a cross-sectional survey of health care providers’ (mainly CHEWs) knowledge and practices 
was conducted in both study arms using a pre-tested, interviewer-administered questionnaire (October 
2016). At the same time, a facility inventory determined availability of commodities and supplies for HDP 
detection and management. Quarterly facility inventory reviews were conducted throughout the 
intervention period in the intervention arm. 
After CHEWs in the intervention arm were trained on HDP detection and management in November 2016, 
a post-training test determined any change in their knowledge of HDPs.  
At endline, in November 2017, a provider survey of the trained CHEWs arm assessed their knowledge 
retention. All case notes from enrolled clients were retrieved and reviewed to determine how clients were 
identified, classified, and managed, in addition to the quality of care provided by CHEWs.  
Lastly, in November 2017 in-depth interviews (IDIs) with women diagnosed with HDPs helped to understand 
their experiences and perceptions of their care from CHEWs, including their perceptions of their pregnancy 
outcomes. Table 2 charts the data collected at baseline and endline. 
Table 2: Data collection activities and number of participants 








CHEW interviews 43 36 36* 29 0 37+ 
Clients enrolled with HDP   40   14 
IDIs with women with HDPs  
(subset of enrolled clients) 
  25   9 
Facility Inventory  20  20 20  20 
*7 CHEWs were not available at endline: + 8 additional CHEWs in the comparison arm 
DATA MANAGEMENT AND ANALYSIS  
All completed questionnaires were transferred immediately to the Council’s Abuja office for data entry and 
analysis. All hard copies of questionnaires, consent forms, and client case notes were sealed and stored in 
secured, locked drawers at the Council office. They will be stored for five years before being destroyed.  
Data were analyzed with STATA, presented in frequency tables. To answer “Are lower level service providers 
able to identify, classify, and manage hypertensive disorders in pregnant women and manage 
appropriately with alpha methyldopa?”, a chi-square/Fisher’s exact test determined associations among 
categorical variables. A non-linear difference in difference analysis determined the intervention’s effects 
while accounting for baseline differences. P-values <0.05 are considered statistically significant. 
Outcomes such as how well HDP was controlled, CVA incidence, and maternal and fetal survival were 
assessed. Analysis considered whether CHEWs correctly diagnosed and categorized HDPs, as well as 
women’s gestation at initial ANC, diagnosis, and study enrolment. Women diagnosed with moderate 




and MgS04, as appropriate. Women referred to higher facilities for definitive management were reported 
upon, and women’s gestation at delivery, fetal and maternal outcomes were determined.  
To evaluate clients’ quality of care, tests of association were conducted, looking closely at client case notes. 
Qualitative data from IDIs with women who experienced PE/E were digitally recorded, transcribed, 
translated, and analyzed to understand women’s perspectives about their quality of care from CHEWs at 
PHCs as well as at referral facilities.  
ETHICAL REVIEW AND CONSENT  
Ethical approval of this study’s protocol was obtained from the Population Council’s Institutional Review 
Board (IRB Protocol 760) in New York, in addition to the National Health Research Ethics Committee 
(NHREC) at the Federal Ministry of Health (FMoH) in Nigeria as well as the Ebonyi State Research Ethics 
Committee (MOH/ET/POP/0022/16). All participants (CHEWS and enrolled women) provided their own 
informed consent for enrollment and subsequent interviews. Administrative and collaborative approval was 
obtained from Ebonyi’s SMoH and LGA local health authorities.  
Enrolled women’s information was documented by CHEWs, including telephone number and community 
name, for ease of follow up. A doctor of medicine from SMoH provided quality control and followed up on 







The key findings from this intervention include the experiences and perspectives of clients enrolled in the 
study. Table 3 describes basic the characteristics of participating CHEWs at both the intervention and 
control PHCs, at baseline and endline. There were no significant socio-demographic differences between 
the two arms, but their differences in work experience neared significance (P=0.05). 
Table 3: CHEWs baseline and endline demographic characteristics  
Characteristic  
















Female 88.4 88.9 93.1 97.3 90.3 93.2 
0.2* 
Male 11.6 11.1 6.9 2.7 9.7 6.8 
Age (years), %≠ 
15 - 25 11.6 8.3 3.4 8.1 8.3 8.2 
0.4 
>25 -35 20.9 13.9 34.5 24.3 26.4 19.2 
>35 - 45 44.2 50.0 31.0 45.9 38.9 47.9 
>45 23.3 27.8 31.0 21.6 26.4 24.7 
Work experience (years), %≠ 
< 1 year 23.3 2.8 6.9 45.9 16.7 24.7 
0.05 1- 3 years 34.9 50.0 41.4 16.2 37.5 32.9 
>3 years 41.9 47.2 51.7 37.8 45.8 42.5 
RMNCH training in the last 3 years, %≠ 
Yes 67.4 100.0 75.9 91.9 70.8 95.9 0.8 
Residence at facility, %≠ 
Yes 48.8 33.3 34.5 32.4 43.1 32.9 0.3 
†  Comparing intervention to control; * Fisher’s Exact test; ≠  Column percentages; RMNCH—reproductive, maternal, neonatal and child health 
Table 4: Intervention effects on CHEW HDP management, intervention and comparison arms 











n %† n %† n %† 
Correct description of BP measurement  46 58.2 21 31.8 67 46.2 <0.001 0.78 
CHEWs correctly defining HDP 50 63.3 34 51.5 84 57.9 0.02 0.36 
CHEWs correctly grading hypertension  26 32.9 3 4.5 29 20.0 0.03 0.60 
% of providers who properly described 
how to manage BP 
44 55.8 17 25.8 61 42.1 0.001 0.57 
Knowledge of when to introduce  
anti-hypertensive drugs 
37 46.8 8 12.1 45 31.0 <0.001 0.38 
Knowledge of when to stop  
anti-hypertensive drugs 
31 39.2 4 6.1 35 24.1 0.03 0.52 
Knowledge of when to rapidly lower 
stroke risk in pre-eclampsic women 
34 43.0 17 25.8 51 35.2 0.008 0.49 
Knowledge of when to administer 
MgS04 to pre-eclampsic women 
40 50.6 21 31.8 61 42.1 0.02 0.41 
†  n/N*100. ‡P-value of the difference-in-differences estimate accounting for baseline differences in intervention and comparison arms; 
P<0.05 considered statistically significant; ^  Average effect of training on CHEW HDP management in the intervention vs. comparison arm 1 
                                                                        
 
 





Table 4 on the preceding page shows that the training’s implementation was followed by a change in 
CHEWs’ knowledge and ability to manage HDPs. 
Table 5 shows that CHEWs in the intervention arm had improved knowledge and abilities to distinguish 
PE/E from other forms of hypertension than those in the comparison arm. 
Table 5: CHEWs ability to distinguish between forms of hypertensive disorders in pregnancy across 
intervention and comparison arms 









n %† n %† n %† 
Chronic  34 43.0 16 24.2 50 34.5 0.1 0.35 
Gestational  36 45.6 20 30.3 56 38.6 0.6 0.18 
Pre-eclampsia 51 64.6 32 48.5 83 57.2 <0.001 0.59 
Severe pre-eclampsia 32 40.5 18 27.3 50 34.5 _* _* 
Eclampsia 55 69.6 44 66.7 99 68.3 0.01 0.41 
 * 72 observations not reported for this variable, hence no meaningful analysis; †  n/N*100; ^ The average effect of the training on CHEWs 
ability to distinguish types of HYPERTENSION in the intervention arm over the comparison arm; ‡  P-value of the difference-in-differences 
estimate; accounting for baseline differences in the intervention and comparison arms; P<0.05 is considered statistically significant; 
Significant results in bold 
In both the intervention and comparison arms, CHEWs mostly identified alpha methyldopa and Nifedipine 
as the drug of choice for controlling BP (Table 6). In addition, alpha methyldopa was the most prescribed 
anti-hypertensive drug in both arms, however, prescription of this drug did not differ between the 
intervention and control arms. At endline, almost no CHEW in either arm prescribed hydralazine, despite 
intervention CHEWs’ awareness of it as a drug used to control BP.  







n %‡ n %‡ n %‡ 
What specific drugs are used to control BP? † 
Labetalol 7 8.9 5 7.6 12 8.3 0.7 
alpha methyldopa/Aldomet 39 49.4 20 30.3 59 40.7 0.02 
Nifedipine 37 46.8 26 39.4 63 43.4 0.4 
Hydralazine 9 11.4 9 13.6 18 12.4 0.7 
Aware/ever heard of alpha methyldopa? 54 68.4 39 59.1 93 64.1 0.2 
Prescribe anti-hypertensive in facility 47 59.5 33 50.0 80 55.2 0.25 
Most commonly prescribed anti-hypertensive≠ 
Labetalol 13 27.7 1 3.0 14 17.5 0.006* 
alpha methyldopa/Aldomet 23 48.9 14 42.4 37 46.3 0.6 
Nifedipine  7 14.9 10 30.3 17 21.3 0.1 
Hydralazine  2 4.3 3 9.1 5 6.3 0.6* 
† Multiple response questions; ‡ n/N*100; * Fisher’s exact test; a Chi-square test, unless otherwise stated; ≠  Brand of anti-hypertensive to 
be prescribed could be influenced by other facility level factors and not necessarily the intervention; Significant results in bold 
 
                                                                        
 
 
2  Due to the multiple response questions and the low number of responses in this section, a difference in difference analysis accounting 




MANAGEMENT OF WOMEN WITH HYPERTENSION IN PREGNANCY  
There were no significant differences between the two study arms in gestational age at booking or 
gestational age at diagnosis. We found a difference in gestational age at delivery between the two study 
arms (P=0.02), but this difference may be due to the fewer women in the comparison arm (n=14). 








n (%) n (%) n (%) 
Gestational age on booking 




21-25 weeks 5 (21.5) 1 (7.1) 6 (11.1) 
26-30 weeks 6 (15.0) 3 (21.4) 9 (16.7) 
31-35 weeks 4 (10.0) 0 (0.0) 4 (7.4) 
36-40 weeks 6 (16.0) 2 (14.3) 8 (14.8) 
Did not report 6 (15.0) 3 (21.4) 9 (16.7 
Gestational age on diagnosis/enrollment 
12-20 weeks 6 (15.0) 3 (21.4) 9 (16.7)  
 
0.2* 
21-25 weeks 6 (15.0) 1 (7.1) 7 (13.0) 
26-30 weeks 9 (22.5) 3 (21.4) 12 (22.2) 
31-35 weeks 7 (17.5) 4 (28.7) 11 (20.4) 
36-40 weeks 8 (20.0) 3 (21.4) 11 (20.4) 
Did not report 4 (10.0) 0 (0.0) 4 (7.3) 
Gestational age at delivery 
<36 weeks  5 (12.5) 6 (42.9) 11 (20.4)  
0.02* 36 weeks and above  31 (77.5) 5 (35.7) 36 (66.7) 
Did not record 4 (10.0) 3 (21.4) 7 (12.9) 
Significant results in bold; * Fisher’s exact test 
 
Following CHEWs’ training, only one client seen at an intervention PHC center was mis-classified for HDP 
and its severity. By contrast, CHEWs in the comparison arm misclassified nine women (see Table 8, 
following page). 
Among women with moderate to severe hypertension requiring anti-hypertensive drugs upon diagnosis, 
more women in the intervention arm received treatment (p<0.001). Furthermore, 50 percent of women 
with severe pre-eclampsia in the intervention arm received a loading dose of MgSO4 upon diagnosis, while 
no woman in the comparison arm received a MgSO4 loading dose (Table 8). 
During this study’s duration, a total of five maternal deaths occurred—one in the intervention arm 
(intrapartum death) and four in the comparison arm (one antepartum, 2 intrapartum, one postpartum). The 
woman who died in the intervention arm did not receive a loading dose of MgSO4 after her diagnosis of 
severe pre-eclampsia; all women who received a loading dose survived. A total of 13 fetal deaths also 
occurred: four in the intervention arm (3 stillbirths, one early neonatal death) and nine in the comparison 
arm (all stillbirths). No mothers of the infants who died received a loading dose of MgSO4.  
These maternal and perinatal deaths were due to a combination of MgSO4 unavailability at facilities, at the 
time of diagnosis of severe PE/E, and client failures to complete the referral process—and not receive the 
drug. Upon study recruitment (immediately after diagnosis), only four women were given anti-hypertensive 
drugs in the comparison arm, yet 29 in the intervention arm were. Similarly, of the women diagnosed with 
severe PE/E at recruitment, only nine women were given MgSO4 (2 in the comparison arm and 7 in the 




Table 8: Pregnancy outcomes among women with HDPs recruited, intervention and comparison 
Pregnancy outcomes among women enrolled  







n (%) n (%) n (%) 
Diagnosis at enrollment 
Correctly Diagnosed Pre-Eclampsia 1 (2.5) 1 (7.1) 2 (3.7) 
<0.001* 
Correctly diagnosed Severe PE 15 (37.5) 0 (0.0) 15 (27.8) 
Correctly diagnosed Gestational Hypertension 21 (52.5) 1(7.1) 22 (40.7) 
Correctly diagnosed Chronic Hypertension 2 (5.0) 3(21.4) 5 (9.3) 
Mis-classified 1 (2.5) 9(64.4) 10 (18.5) 
Correct HDP classification at enrollment: mild, moderate, severe/chronic, gestational/PE, severe PE/E  
Yes 37 (92.5) 1 (7.1) 38(70.4) 
<0.001* 
No  3 (7.5) 13 (92.9) 16 (29.6) 
Received anti-hypertensive on diagnosis at recruitment for moderate to severe hypertension, severe PE/E 
Yes  29 (72.5) 4 (28.6) 33 (61.1 
0.002* 
No  10 (71.1) 11 (27.5) 21 (38.9) 
Received MgSO4 on diagnosis at enrollment 
Yes  7 (17.5) 2 (14.3) 9 (16.7) 
0.9* 
No  33 (82.5) 12 (85.7) 45 (83.3) 
Anti-hypertensive at first follow up after diagnosis of moderate to severe hypertension, severe PE/E   
Yes  21 (60.0) 2 (18.2) 23 (50.0) 
0.02* 
No  14 (40.0) 9 (81.8) 23 (50.0) 
Received MgSO4 on diagnosis at enrollment 
Yes  5 (14.3) 2 (18.2) 7 (15.2) 
0.8* 
No  30 (85.7) 9 (81.8) 39 (84.8 
Number of pregnant women referred 8 (20.0) 2 (14.3) 10 (18.5) 0.7 
Fetal outcome 
Alive 36 (90.0) 5 (35.7) 41 (75.9) 
<0.001* Dead  4 (10.0) 9 (64.3) 13 (24.1) 
Total  40 (100.0) 14 (100.0) 54 (100.0) 
Maternal outcome 
Alive 39 (97.5) 10 (71.4) 49 (90.7)  
0.004* Dead  1 (2.5) 4 (28.6) 5 (9.3) 
Total 40(100.0) 14 (100.0) 54 (100.0) 
a Chi-square test, unless otherwise stated; *Fisher’s exact test; Significant results in bold 
More children survived with early administration of anti-hypertensive drugs to women with moderate to 
severe hypertension, and a loading dose of MgSO4 to women with severe pre-eclampsia (p<0.005). No 
women who received MgSO4 died in the intervention arm.  
 Table 9. Effects of MgSO4 and anti-hypertensive on fetal and maternal survival 
 Intervention Comparison Total p-value 
Diagnosed severe PE/E, received MgSO4 at enrollment—Fetal Survival 
Alive 6 (85.7) 0 (0.0) 6 (66.7) 
<0.001* Dead  1 (14.3) 2 (100.0) 3 (33.3) 
Total  7 (77.8) 2 (22.2) 9 (100.0) 
Diagnosed moderate to severe hypertension, received anti-hypertensive at enrollment—Fetal Survival 
Alive 20 (83.3) 1 (50) 21 (80.8) 
0.003* Dead  4 (16.7) 1 (50) 5 (19.2) 
Total  24 (92.3) 2 (7.7) 26 (100) 
Diagnosed moderate to severe hypertension, received anti-hypertensive at enrollment—Maternal Survival 
Alive 24 (100) 2(100) 26(100.0) 
_‡ Dead  0 (0.0) 0 (0.0) 0 (0.0) 
Total  24(92.3) 2(7.7) 26(100.0) 




FACILITY STOCK REVIEWS 
A pre-post assessment of the 20 facilities from the comparison and intervention arms determined monthly 
availability of commodities for effective HDP management (figures 2 and 3) over the implementation period 
(December 2016 to November 2017). When Ending Eclampsia activities started in June 2016, stocks of 
key supplies was generally poor (Figure 2). Most Ending Eclampsia facilities had no anti-hypertensive drugs, 
calcium gluconate, urine test strips, etc. The project encouraged—and had impact upon—the stocking of 
such commodities (Figure 2). 
An industrial action (or workers’ strike) in June 2017 lasting about two weeks, an effort of the Joint Health 
Sector Union (JOHESU—minus doctors) in Nigeria, lead to reduced supply availability. JOHESU is the largest 
umbrella of the health workforce, therefore any attempt of industrial action can result in total facility 
closures, leading to an inability for SMoH or Central Medical Stores to supply commodities. Consequently, 
when the team visited to collect data during that period, not all facilities had resumed operation, despite 
the resolution of the union to resume work. 
Importantly, this period (June and July 2017) was characterized by extensive and massive health provider 
transfers due to the introduction of PHCUOR (Primary Health Care Under One Roof policy) in Ebonyi, causing 
another reduction in equipment and commodity availability. Some BP machines were not the property of 
facilities but “privately owned,” and left when staff were transferred. In addition, from June until November 
2017, some facilities reported damaged BP machines, which contributed to the reduced availability of 
functional BP machines.  
While all facilities had functional BP machines at baseline, there was a decline in their availability at endline. 
Although stocks of urine test strips, calcium gluconate, MgS04, and anti-hypertensive drugs increased, the 
trend indicates not all facilities consistently stocked these commodities and supplies. MgS04 appeared to 
expire more frequently at facilities in the comparison arm, especially at baseline.  
Figure 2. Availability of commodities and supplies for detecting HDPs in comparison facilities, 
June 2016 – November 2017 
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Figure 3. Availability of commodities and supplies for detecting HDPs in intervention facilities 
June 2016 – November 2017 
 
Note: Facility assessment conducted in 20 PHCs 
 
CLIENT ATTENDANCE AND SERVICES  
More women attended facilities for ANC in the intervention arm (figures 4 and 5). Not every woman received 
BP measurement or urine tests at each visit, although national standards stipulate that every woman 
should be screened at every visit. Following the intervention, more women had BP and urine checked during 
ANC visits than pre-intervention, and this consistently increased overtime: At first ANC visit, 94 percent of 
women had BP measured, while 85 percent had a urine test. 
Figure 4 shows that total BP measurement was slightly higher than total urine tested. Average monthly BP 
measurement was 177 (standard deviation 57.5) and average monthly urine testing was 137 (standard 
deviation 71.8). 
Figure 4. Frequency of ANC visit and HDP screening at comparison facilities  
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Figure 5 illustrates greater total BP measurement than total urine tests. Average monthly BP measurement 
was 433 (standard deviation 93.8) while average monthly urine testing was 307 (standard deviation 
126.3). 
Figure 5. Frequency of ANC visit and HDP screening at intervention facilities 
June 2016 – November 2017 
 
WOMEN’S EXPERIENCES 
This section draws upon qualitative interviews after the intervention with women who experienced PE/E, in 
both the intervention (n=25) and comparison (n=9) sites. Transcripts were reviewed for correctness. The 
team analyzed the transcripts for emerging themes, which resulted in categorization according to: 
1. What women know about hypertension in pregnancy?. 
2. Women’s perceptions about the content of their care  
3. Women’s perceptions of provider prescription habits, commodity supplies, and follow up care 
4. Women’s failure to complete referral processes due to inadequate information from facilities 
5. Women’s perceptions of CHEWs’ care for hypertensive disorders at PHCs, and 
6. Late ANC registration and inconsistent ANC impair early detection and management of HDPs. 
WHAT DO WOMEN KNOW ABOUT HYPERTENSION IN PREGNANCY?  
Women’s understanding and perceptions of HDP varied. Some thought that there are specific symptoms 
that might provoke them to consider they had high BP. Even when symptoms occur (headaches, dizziness) 
women tend to ascribe the symptoms to more familiar health conditions such as malaria in pregnancy.  
“I felt it was malaria that I was having, and I started taking malaria drugs and after taking it, it did 
not stop so I went to the health center where I registered for antenatal care, and they checked me 
and told me that what I am suffering from is not malaria, but it is high blood pressure that I am 
suffering from.”                                    HPD survivor, 22 years of age, multigravida, intervention arm 
Some women could not recognize the onset of their hypertension, while some only realized it after they 
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“I didn’t know I had hypertension. My pregnancy was seven months when I started having 
headache and fever. It was when I went to the maternity and they checked me and told me that I 
have hypertension.”                                            HDP survivor, age 21, primigravida, comparison arm 
Some women in the intervention arm were aware of negative consequences of HDPs, if not properly 
managed, associating HDP with complications such as pre-term birth, miscarriage, maternal death, and 
prolonged maternal morbidity. Women in the intervention arm better understood the need for careful 
management of any hypertension to prevent complications and death.  
“It could have made the baby to go to my heart or I could have delivered the baby when it is not 
due for delivery or they will do it operation.”    HDP survivor, age 30, multigravida, intervention arm 
“Pregnant woman that is having blood pressure [hypertension], if not properly managed the 
person’s child will die. [Health care workers] will start telling the pregnant woman another story.” 
                                                         HDP survivor, age 32, multigravida, intervention arm 
WOMEN’S PERCEPTIONS OF THE CONTENT OF THEIR CARE  
Generally, but especially in intervention communities, women reported high satisfaction and favorable 
opinions of their providers’ attitudes, both for them and their care. Overall, women in the intervention arm 
reported improved care experiences, and many women seen at intervention facilities believe their care was 
adequate. In both arms, women felt respected by their care providers, both at PHC and referral facilities. 
“[The care provider] was very careful giving me blood pressure drugs when I come. Those health 
providers used to take good care of me, if I come, they will start calling me with sweet names and 
they use to play with me, they have good attitude towards me.”  
HDP survivor, age 35, multigravida, intervention arm 
“You know, the health provider that attended to me lives in our community, even though she’s not 
originally from here; but she interacts with us very well, so when we come for antenatal care visits, 
she treats us kindly to make us happy.”           HDP survivor, age 23, primigravida, comparison arm 
This project used health talks and communication to improve women’s knowledge of important pregnancy 
issues and empowered women to ask questions around their health and on any clinical and laboratory 
findings. Similarly, women also reported increased communication between them and their care providers. 
Women received health talks on their necessary health services and actions they should take in cases of 
abnormal results.  
“They used to give us health talks on different topics. What they teach today is not what they will 
teach tomorrow, and that is the first thing they do before conducting health checks on us.”  
HDP survivor, age 28, multigravida, comparison arm 
“Yes, I used to feel very happy whenever I come for antenatal. After giving us a talk and I ask 
questions and after answering me, I will be glad and when I am going, I will not be thinking about 
anything.”                                                            HDP survivor, age 30, multigravida, intervention arm 
While client responses to health talks and communication were impressive, some clients were unhappy 
with their care providers’ explanations of their clinical and laboratory test results. Some women recalled BP 
results shared, but were not told about urine test results. In some cases, health care providers had informed 
women of their test findings, but women could not recall them. Some women in the intervention arm feel 
that health care providers intentionally do not communicate BP and urine tests results, especially when 
findings are abnormally high. Providers on occasion do not reveal findings to clients even when symptoms 




“You know, sometimes these nurses like to hide somethings for their patients. They don’t like telling 
us- like now if my blood pressure is high, they won’t tell me my blood pressure is high, they will tell 
me to go to somewhere else that is higher [higher level facility] than their own facility. That the 
higher facility will treat me the way I am supposed to be treated. So, it’s all these things, sometimes 
I will ask them what my blood pressure is? They will tell me not to worry, but I should go to 
somewhere else that is not something they can handle again.”  
HDP survivor, age 40, multigravida, intervention arm 
“They checked my blood pressure, not urine. She did not tell me anything about my result. It was 
when my husband asked them, ‘Why they are still keeping me?’ that the provider said my blood 
pressure was high.”                                            HDP survivor, age 28, primigravida, comparison arm 
WOMEN’S PERCEPTIONS OF PROVIDER PRESCRIPTION HABITS, COMMODITY 
SUPPLIES AND FOLLOW UP CARE 
Women in the intervention arm reported better prescription practices than those in the comparison arm.  
Some women received appropriate anti-hypertensive drugs but did not know specifics about dosages or 
frequency, and some felt it was usual for health care providers to not provide prescription specifics. Women 
also complained that CHEWs sometimes instruct them to purchase their anti-hypertensive drugs from 
outside sources due to lack of drug availability at facilities:  
“I don’t know, you know, what they normally do in the hospital, is that they give you drugs without 
telling you the name of the drugs. If the drugs names were written [prescribed] for me to go and 
buy it, is then that I will know the names of the drugs. They just gave me [tablets], and I looked at 
it and took [swallowed] it without knowing the names.”  
HDP survivor, age 30, multigravida, intervention arm 
“After those drugs and injections, they saw it was not working. It was then that they referred me to 
Federal Medical Center.”                                   HDP survivor, age 30, multigravida, intervention arm 
Some women who purchased their own drugs, from private sources, reported paying more than they could 
afford. These women recommend the government ensure pro-poor, stable, and accessible drug supplies, 
especially for pregnant women, to mitigate unaffordable health care.  
“The medicine was costly. I paid gradually [in installment] when I don’t have money, but when I 
had money I paid in full.”                                   HDP survivor, age 25, multigravida, comparison arm 
“What I am telling the government is, for them to know how to improve this drug, so that it can 
reach both the rich and the poor. They should be giving it to every pregnant mother, because there 
are some that have finance problem. They should make it affordable for every pregnant woman.” 
HDP survivor, age 27, multigravida, intervention arm 
WOMEN’S FAILURE TO COMPLETE REFERRAL PROCESS—DUE TO INADEQUATE 
INFORMATION FROM REFERRING FACILITIES 
Issues with referrals to higher level facilities remain. While health providers made efforts to refer women to 
for definitive management, some women did not visit referral facilities despite their continuous elevated 
BP. This poses a challenge to PHC HDP management. Even when women complete their referrals, no 
referral process provides continuity of care, especially a dual process reporting back to the PHC facility. As 
a result, women often do not return to their originating PHCs for care after attendance and treatment at 
referral facilities.  
“Yes, I was referred to Federal Medical Center because of the high blood pressure, but I did not go 




Women from both study arms failed to complete their referral process due to lack of detail and discussion 
at their originating PHCs on the reasons for their referrals. These gaps in communication lead to declines 
and non-adherence within the referral process. Some women complained of lack of financial reserves for 
transportation to referral centers. CHEWs sometimes do not refer women to facilities closest to them. 
Women often resort to borrowing to enable travel to referral centers.  
“I usually enter okada [motorcycle] from Ogwor to Afikpo, I will say that it is far, as someone who 
has nothing doing…we are just managing our best, we struggle to eat, he [husband] is trying his 
best, anytime they said come, he will try to make sure that I go even if it means borrowing, he will 
do so to ensure that I went.”                             HDP survivor, age 30, multigravida, intervention arm 
Sometimes women refused the recommended means of care. Some women were recommended for 
hospital admission, but insisted on returning home due to lack of finances. Financial burdens are a 
significant factor in whether women adhere to prescribed care (including referrals).  
“When I got to Afikpo, they found out that I have high blood pressure. They said that they will give 
me bedrest, I told them to allow me to go and look for money. I came back and spent two days at 
the hospital.”                                                       HDP survivor, age 36, multigravida, intervention arm 
WOMEN’S PERCEPTIONS OF CHEWs’ CARE FOR HYPERTENSION IN PREGNANCY 
Women in the intervention arm were accepting of CHEWs’ care provision. Some women mentioned CHEWs’ 
importance at PHCs, for attending to pregnant women, including HDP care. These women’s views reflect 
CHEWs’ perceived respect for women’s dignity. 
“Had it been that I didn’t come to this health center, I didn’t know what could have been the 
condition of me and my baby, because this health center is really trying in to provide services. They 
take care of pregnant women very well, especially in the area of hypertension.”  
HDP survivor, age 27, multigravida, intervention arm 
LATE ANTENATAL CARE REGISTRATION AND INCONSISTENT CONTACT IMPAIR 
EARLY DETECTION AND MANAGEMENT OF HYPERTENSION IN PREGNANCY 
Late ANC registration is still common. Generally, pregnant women’s first ANC contact is after 20 weeks’ 
gestation—in both study groups. Women also appear to simultaneously register in at least two facilities for 
ANC. In some cases, women were already having complications by the time of their initial ANC at a facility:  
“I know that I did not start antenatal on time. It was when I started feeling somehow [abnormal] 
that my husband insisted that I should go to the maternity and register. By that time, I was six 
months pregnant.”                                              HDP survivor, age 30, primigravida, comparison arm 
In addition to registering for ANC at multiple facilities, women may also seek care from religious groups or 
traditional birth attendants, due to pressure from friends and family.  
“I went to the tradition medicine when I was pregnant, you know that if you have problem, many 
people will be suggesting and advising you to go here or there, you will continue to move from one 
place to another.”                                               HDP survivor, age 38, multigravida, comparison arm 
“Let me tell you, I came here [PHC center] to confirm my pregnancy, and that was at 18 weeks, but 
I’m used to receiving treatment at Mama Mgbo [a traditional birth attendant].”  






Given HDPs’ contribution to maternal and perinatal deaths in Nigeria1-2, 6, coupled with the increasing 
recognition that providers at lower levels (such as PHC) of the health system are a vital point of care for 
women and children, this project aimed to test the feasibility of CHEWs to detect and manage HDP using 
alpha methyldopa, as well as MgSO4 administration and referral in selected cases.  
This study shows that CHEWs in the intervention sites were able to correctly measure BP and manage HDP. 
CHEWs at intervention PHC centers were 60 percent more likely to correctly grade hypertension as mild, 
moderate, or severe, an essential step for effective HDP management of women seeking lower level health 
care. Those CHEWs were also better able to differentiate HDPs as chronic hypertension, gestational 
hypertension, or pre-eclampsia. More women attended ANC in the intervention arm, but their BP was not 
measured, nor urine tested, at every contact. While in resource-poor environments only testing urine for 
proteinuria for BP over 140/90 may be understandable, there should be no excuse for not measuring BP 
at every contact. A recent study of facility readiness in sub-Saharan Africa showed particularly poor abilities 
to manage HDP, indicating that measurement of BP alone may not be adequate for quality care, however26. 
CHEWs at intervention PHCs also appropriately prescribed alpha methyldopa to pregnant women with 
moderately severe hypertension. Essential maternal health commodities such as MgSO4 and urine dipstick 
were more frequently available at intervention facilities, indicating that the intervention affected and 
improved the supply chain and logistics system. Although facilities in the comparison arm (as are all PHCs 
in Nigeria) were already mandated by the national task shifting policy to provide a loading dose of MgSO4 
and other basic obstetrics services, this intervention has demonstrated that it is possible to integrate an 
additional service to more holistically manage women with HDPs. 
CHEWs’ MgSO4 knowledge and use, for women with severe PE/E, improved by 55 percent. Half of all women 
managed at intervention facilities were administered a loading dose of MgSO4, as opposed to none at 
comparison sites. This provides the needed evidence and support to begin the empowerment of CHEWs to 
provide these services more broadly at the PHC level in Nigeria, and in other places with a similar health 
system structure. A similar study in Nigeria supports CHEW provision of a loading dose of MgSO4 to women 
with severe PE/E8, 11. 
Maternal and perinatal outcomes were better among women managed at intervention PHCs. The sample 
sizes in both study groups (40 and 14 women, respectively) were too small for firm conclusions, but these 
results show potential for this sort of PHC intervention. Where provider skills are enhanced, and essential 
commodities become more available, health outcomes will consequently improve, as seen in this study, 
and demonstrated in others27-29. 
Women’s perceptions and experience of their use of PHC services were very encouraging. Women maintain 
favorable opinions and that their CHEWs provided adequate information, through health talks on various 
ANC issues, with cordiality by their providers30. CHEWs must, however, improve their communication of 
critical information to clients, to accurately convey clients’ severity of condition to them. In some instances 
CHEWs did not provide adequate information on use of drugs supplied or prescribed. Some women also 
felt that CHEWs “concealed information” from them about their diagnoses, possibly due to the belief their 
clients were better not knowing about their condition severity. If women and their families do not know or 
understand how serious their medical conditions are, and their potential consequences, they may be less 
likely to urgently seek care.  
Local and state governments must fulfill their responsibilities for ensuring essential tools and commodities 





Community health extension workers at primary health care facilities can correctly measure blood pressure, 
and detect abnormal blood pressure, and thereafter accordingly begin treatment for severe pre-eclampsia 
and eclampsia and refer cases to higher level facilities for further management. Although challenges 
remain in ensuring that enough commodities and supplies are continuously available, this study 
demonstrates how ministries of Health can utilize these essential health workers, and arrest missed 
opportunities, to detect pre-eclampsia—and potentially, other conditions—and prevent deterioration by 
providing anti-hypertensives and magnesium sulphate to stabilize women with hypertensive disorders in 
pregnancy and refer them for appropriate, and often life-saving, continuing treatment. 
Recommendations—and Challenges—to Consider for Scale Up 
 Disseminate findings to the Federal Ministry of Health and partners, to consider incorporation 
within task shifting guidelines.  
 The State Ministry of Health should ensure consistent commodities and supplies for managing 
hypertensive disorders in pregnancy within primary health care.  
 The importance of early care seeking in pregnancy and frequent checkups should be emphasized 
to community members, especially through women’s groups. 
 Community health extension workers should be updated in importance of information-sharing 
with women and families. 
 Women should be seen as active partners in their health care.  
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